Skip to main content
Soumya Raychaudhuri, MD, Rheumatology, Boston, MA, Brigham and Women's Hospital

SoumyaRaychaudhuriMDPhD

Rheumatology Boston, MA

Professor of Medicine, Harvard Medical School. JS Coblyn and MB Brenner Distinguished Chair, Brigham & Women's Hospital

Dr. Raychaudhuri is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Raychaudhuri's full profile

Already have an account?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Rheumatology, 2006 - 2010
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2004 - 2006
  • Stanford University School of Medicine
    Stanford University School of MedicineClass of 2004

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2006 - 2025
  • American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

  • Fellow (FACR) American College of Rheumatology

Publications & Presentations

PubMed

Journal Articles

  • High-Throughput Identification of Noncoding Functional SNPs via Type IIS Enzyme Restriction  
    Soumya Raychaudhuri, Jing Cui, Michael B Brenner, Peter A Nigrovic, Nature
  • Methods for High-Dimensonal Analysis of Cells Dissociated from Cyropreserved Synovial Tissue  
    Paul J Utz, William H Robinson, Ellen M Gravallese, Soumya Raychaudhuri, Alessandra B Pernis, Susan M Goodman, Michael B Brenner, Lionel B Ivashkiv, Brendan F Boyce, P..., BioMed Central

Other

Authored Content

  • RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis FlaresJuly 2020
  • RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis FlaresJuly 2020

Press Mentions

  • Mestag Therapeutics Launches with $11m for Fibroblast Goal
    Mestag Therapeutics Launches with $11m for Fibroblast GoalApril 30th, 2021
  • Newborn Bio Business Mestag Therapeutics Raises $11m Seed Cash
    Newborn Bio Business Mestag Therapeutics Raises $11m Seed CashApril 26th, 2021
  • Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations Across Inflammatory Disease and Cancer
    Mestag Therapeutics Launches with Seed Financing of $11 Million to Develop Therapeutics Targeting Activated Fibroblast Populations Across Inflammatory Disease and CancerApril 20th, 2021
  • Join now to see all

Professional Memberships

Hospital Affiliations